Axsome Therapeutics
AXSM
219 hedge funds and large institutions have $2.32B invested in Axsome Therapeutics in 2022 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 57 increasing their positions, 74 reducing their positions, and 26 closing their positions.
138% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 26
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
102% more capital invested
Capital invested by funds: $1.15B → $2.32B (+$1.17B)
35% more call options, than puts
Call options by funds: $179M | Put options by funds: $133M
17% more funds holding
Funds holding: 187 → 219 (+32)
5.48% more ownership
Funds ownership: 63.74% → 69.22% (+5.5%)
23% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$105M |
| 2 |
RI
RTW Investments
New York
|
+$65.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$54.7M |
| 4 |
VA
VR Adviser
New York
|
+$40.1M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$51.9M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$34.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$33.9M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$23.2M |
| 5 |
Millennium Management
New York
|
-$15.7M |
AXSM Hedge Fund Activity: Q4 2022 in Review
219 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2022, worth a combined $2.32B — up 102% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new AXSM positions and 26 closed out — a net gain of 36 holders — while 57 added to existing stakes and 74 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $105M. The largest seller was Avidity Partners Management, cutting an estimated $51.9M.
- 219 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2022, up from 187 in Q3 2022.
- Funds reported $2.32B of Axsome Therapeutics stock for Q4 2022, up 102% quarter-over-quarter.
- 62 funds opened new Axsome Therapeutics positions in Q4 2022 and 26 closed out, a net change of +36 holders.
- The largest Axsome Therapeutics buyer in Q4 2022 was BVF Inc, an estimated $105M added.
- The largest Axsome Therapeutics seller in Q4 2022 was Avidity Partners Management, an estimated $51.9M sold.
Based on aggregated 13F filings for Q4 2022.